Search

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes.

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

Faculty information

We are honored that you have agreed to be part of the faculty for the EHA Research Conference "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis", scheduled to take place in Málaga, Spain, on March 17-20, 2025.

Read more

Publications

Original scientific publications
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Fandrei D, Huynh T, Sébert M, Aguinaga L, Bisio V, Kim R, Clappier E, Espéli M, Balabanian K, Moins-Teisserenc H, Toubert A, Dulphy N, Fenaux…

Read more

Previous awards

Before the introduction of its current awards program, EHA honored:

Leaders in hematological research through the José Carreras Award (from 1999)
Outstanding physicians and scientists by means of the Jean Bernard Lifetime Achievement Award (from 2008)
In 2018, two further awards were introduced…

Read more

EHA2023 Gallery

We extend our gratitude to the esteemed Faculty, delegates, and industry partners for their valuable contributions to the EHA2023 Hybrid Congress.

Read more